CD19 and neoplasm: Unlike hematologic malignancies, where CD19-targeted CAR-T therapy has been highly successful, the effectiveness of CAR-T therapy in HNSCC relies on selecting tumor-specific antigens that ensure high tumor selectivity while minimizing off-target effects.